CHEYNEY, Pa. and SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the expanded collaboration to develop ADCs targeting humoral immuno-suppressed cancers.
February 4, 2020
· 2 min read